CLU and Alzheimer disease: Several recent studies demonstrated that CSF and circulatory clusterin levels serve as a prognostic and/or diagnostic biomarker for neuropathologies such as Alzheimer’s disease (AD), mild cognitive impairment, multiple sclerosis, acute ischemic stroke, and epilepsy19–31.